The Perigenomed initiative in France is pioneering routine genome sequencing-based newborn screening to detect hundreds of treatable rare diseases before symptoms emerge. CHU Dijon has sequenced 500 infants already using Illumina technology, identifying seven cases of rare diseases. The project will expand across additional hospitals aiming to sequence 2,500 newborns by early 2026, with a second phase planned to evaluate clinical utility and economics across broader populations. Funded with state and private support totaling around €13 million, the efforts seek to integrate genomic screening into standard neonatal care.